This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism.
The National Cancer Institute invites applications for its utilising the prostate, lung, colorectal and ovarian cancer (PLCO) biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01 clinical trial not allowed) funding opportunity. This supports research in cancer aetiology and early-detection biomarkers, using the biorepository resources of the NCI-sponsored PLCO screening trial. Projects may be in a wide range of cancer research, including biochemical and genetic analyses of cancer risk and discovery and validation of early detection biomarkers. Proposed research must make use of the PLCO biospecimens and should take advantage of the unique nature of the specimens.
Funding & Duration
Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- 11 January 2019 – Letter of Intent submitted directly to Sponsor
- 28 January 2019 – applications submitted for internal review
- Please email firstname.lastname@example.org if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review